RS65417B1 - Diaril makrocikli kao modulatori protein kinaza - Google Patents
Diaril makrocikli kao modulatori protein kinazaInfo
- Publication number
- RS65417B1 RS65417B1 RS20240447A RSP20240447A RS65417B1 RS 65417 B1 RS65417 B1 RS 65417B1 RS 20240447 A RS20240447 A RS 20240447A RS P20240447 A RSP20240447 A RS P20240447A RS 65417 B1 RS65417 B1 RS 65417B1
- Authority
- RS
- Serbia
- Prior art keywords
- mmol
- mixture
- compound
- added
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931506P | 2014-01-24 | 2014-01-24 | |
| US201462049326P | 2014-09-11 | 2014-09-11 | |
| US201562106301P | 2015-01-22 | 2015-01-22 | |
| EP19212110.1A EP3636649B1 (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65417B1 true RS65417B1 (sr) | 2024-05-31 |
Family
ID=53682127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240447A RS65417B1 (sr) | 2014-01-24 | 2015-01-23 | Diaril makrocikli kao modulatori protein kinaza |
| RS20190900A RS59059B1 (sr) | 2014-01-24 | 2015-01-23 | Diaril makrociklična jedinjenja kao modulatori protein kinaza |
| RS20221161A RS63829B1 (sr) | 2014-01-24 | 2015-01-23 | Diaril makrociklična jedinjenja kao modulatori protein kinaza |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20190900A RS59059B1 (sr) | 2014-01-24 | 2015-01-23 | Diaril makrociklična jedinjenja kao modulatori protein kinaza |
| RS20221161A RS63829B1 (sr) | 2014-01-24 | 2015-01-23 | Diaril makrociklična jedinjenja kao modulatori protein kinaza |
Country Status (35)
| Country | Link |
|---|---|
| US (7) | USRE50634E1 (OSRAM) |
| EP (6) | EP3636650A1 (OSRAM) |
| JP (5) | JP6490713B2 (OSRAM) |
| KR (1) | KR102402179B1 (OSRAM) |
| CN (3) | CN110317213B (OSRAM) |
| AP (1) | AP2016009383A0 (OSRAM) |
| AU (2) | AU2015209239B2 (OSRAM) |
| CA (1) | CA2936079C (OSRAM) |
| CL (1) | CL2016001876A1 (OSRAM) |
| CY (1) | CY1121850T1 (OSRAM) |
| DK (3) | DK3572416T3 (OSRAM) |
| EA (2) | EA031863B1 (OSRAM) |
| ES (3) | ES2735729T3 (OSRAM) |
| FI (2) | FI3636649T3 (OSRAM) |
| FR (1) | FR25C1013I1 (OSRAM) |
| HR (3) | HRP20191283T1 (OSRAM) |
| HU (4) | HUE060554T2 (OSRAM) |
| IL (2) | IL246860B (OSRAM) |
| LT (4) | LT3097107T (OSRAM) |
| MX (2) | MX392904B (OSRAM) |
| MY (1) | MY193524A (OSRAM) |
| NL (1) | NL301322I2 (OSRAM) |
| NO (1) | NO2025015I1 (OSRAM) |
| NZ (2) | NZ761094A (OSRAM) |
| PE (1) | PE20160931A1 (OSRAM) |
| PH (1) | PH12016501463A1 (OSRAM) |
| PL (3) | PL3636649T3 (OSRAM) |
| PT (3) | PT3572416T (OSRAM) |
| RS (3) | RS65417B1 (OSRAM) |
| SG (2) | SG10202000191YA (OSRAM) |
| SI (3) | SI3097107T1 (OSRAM) |
| SM (3) | SMT202400175T1 (OSRAM) |
| UA (1) | UA121206C2 (OSRAM) |
| WO (1) | WO2015112806A2 (OSRAM) |
| ZA (2) | ZA201604654B (OSRAM) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| USRE50634E1 (en) | 2014-01-24 | 2025-10-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| MA41667A1 (fr) | 2015-06-01 | 2018-08-31 | Loxo Oncology Inc | Procede de diagnostic et de traitement du cancer |
| RU2732405C2 (ru) * | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| LT3319969T (lt) | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
| EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
| US20180325901A1 (en) * | 2015-07-21 | 2018-11-15 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017106505A1 (en) * | 2015-12-15 | 2017-06-22 | University Of South Florida | Gas5 binding compounds, formulations, and uses thereof |
| EP3439663B1 (en) | 2016-04-04 | 2024-07-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| BR112019001607A2 (pt) * | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN107586796B (zh) * | 2017-07-20 | 2021-08-06 | 暨明医药科技（苏州）有限公司 | (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法 |
| ES2986593T3 (es) | 2017-07-28 | 2024-11-12 | Turning Point Therapeutics Inc | Compuestos macrocíclicos y usos de los mismos |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| WO2019094143A1 (en) * | 2017-11-10 | 2019-05-16 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| CN111511746B (zh) * | 2017-12-19 | 2024-01-09 | 特普医药公司 | 用于治疗疾病的巨环化合物 |
| US20210087206A1 (en) | 2017-12-19 | 2021-03-25 | Turning Point Therapeutics, Inc. | Macrocyclic kinase inhibitors and their use |
| EP3730492A4 (en) * | 2017-12-22 | 2021-08-11 | Shenzhen TargetRx, Inc. | COMPOUND PYRAZOLO [1,5-A] PYRIMIDINE SUBSTITUTE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN109575025B (zh) * | 2018-01-23 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| TW201932472A (zh) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| BR112020019399A2 (pt) * | 2018-03-28 | 2021-01-05 | Fochon Pharmaceuticals, Ltd. | Compostos macrocíclicos como inibidores de trk quinases |
| US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| WO2019201131A1 (zh) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
| ES2989075T3 (es) * | 2018-04-25 | 2024-11-25 | Primegene Beijing Co Ltd | Compuesto macrocíclico diarílico y composición farmacéutica y uso del mismo |
| CN111918868B (zh) * | 2018-05-04 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| CN110950889B (zh) * | 2018-09-27 | 2022-04-05 | 北京赛林泰医药技术有限公司 | 一种多靶点激酶抑制剂及其制备方法和用途 |
| JP2022511381A (ja) * | 2018-09-29 | 2022-01-31 | シャンドン ルイ ファーマシューティカル カンパニー リミテッド | 選択的Ｔｒｋ阻害剤としてのピラゾロピリミジン誘導体 |
| FI3870579T3 (fi) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibiittoreita ja niiden käyttöjä |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| WO2020094112A1 (zh) * | 2018-11-09 | 2020-05-14 | 山东轩竹医药科技有限公司 | 大环类酪氨酸激酶抑制剂及其用途 |
| US12157741B2 (en) * | 2018-11-19 | 2024-12-03 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of DYRK1A |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| CN111592541B (zh) * | 2019-02-21 | 2021-09-10 | 山东轩竹医药科技有限公司 | 大环类激酶抑制剂及其用途 |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| CA3134814A1 (en) * | 2019-03-26 | 2020-10-01 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| WO2020233645A1 (zh) * | 2019-05-21 | 2020-11-26 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2020257169A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Polymorphs of a macrocyclic kinase inhibitor |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| JP7617861B2 (ja) * | 2019-06-21 | 2025-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の大環状阻害剤 |
| CN113773335B (zh) * | 2019-06-21 | 2024-12-03 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
| TW202116765A (zh) | 2019-07-16 | 2021-05-01 | 美商邁奧卡迪亞公司 | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺醯基)-1-氟乙基)-n-(異噁唑-3-基)哌啶-1-甲醯胺之多晶型物形式 |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| CA3163095A1 (en) | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| EP4065125A4 (en) | 2019-11-27 | 2024-01-03 | Turning Point Therapeutics, Inc. | COMBINATION THERAPY WITH DIARYL MACROCYCLIC COMPOUNDS |
| TW202134249A (zh) | 2019-12-03 | 2021-09-16 | 美商特普醫葯公司 | 用於治療疾病的巨環 |
| WO2021113492A1 (en) | 2019-12-06 | 2021-06-10 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| CA3161339A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| CN113045587A (zh) * | 2019-12-27 | 2021-06-29 | 成都倍特药业股份有限公司 | 一种大环结构化合物的晶型及其制备方法 |
| CN113135938B (zh) * | 2020-01-19 | 2022-06-14 | 山东轩竹医药科技有限公司 | 取代的大环类酪氨酸激酶抑制剂及其用途 |
| US20250262216A1 (en) * | 2020-03-02 | 2025-08-21 | Turning Point Therapeutics, Inc. | Therapeutic uses of macrocyclic compounds |
| AU2021267161A1 (en) | 2020-05-04 | 2022-12-08 | Amgen Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
| WO2021223748A1 (zh) * | 2020-05-08 | 2021-11-11 | 山东轩竹医药科技有限公司 | 大环类酪氨酸激酶抑制剂的晶型及其制备方法 |
| EP4163283A1 (en) * | 2020-06-04 | 2023-04-12 | Scinnohub Pharmaceutical Co., Ltd | Compound having macrocyclic structure and use thereof |
| CN116171279A (zh) * | 2020-07-10 | 2023-05-26 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| WO2022164789A1 (en) | 2021-01-26 | 2022-08-04 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disoders |
| WO2022182845A1 (en) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113754657B (zh) * | 2021-09-22 | 2023-01-17 | 广州白云山医药集团股份有限公司白云山制药总厂 | 大环类化合物的晶型及其制备方法和应用 |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| CN116514813A (zh) * | 2021-12-31 | 2023-08-01 | 轩竹生物科技股份有限公司 | 酪氨酸激酶抑制剂及其中间体的制备方法 |
| US20250074920A1 (en) * | 2022-01-05 | 2025-03-06 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as kinase inhibitors |
| CN115746023B (zh) * | 2022-10-27 | 2024-08-09 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2025217347A2 (en) | 2024-04-11 | 2025-10-16 | Bristol-Myers Squibb Company | Process of preparing repotrectinib |
| WO2025235733A1 (en) * | 2024-05-09 | 2025-11-13 | Blossomhill Therapeutics, Inc. | Bis-bicycloheteroaryl macrocycles and their use |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| ES2021105B3 (es) | 1987-03-07 | 1991-10-16 | Bayer Ag | Procedimiento para la obtencion de 5-amino-4,6-dihalogeno piridinas. |
| EP0690843B1 (en) | 1993-03-25 | 2000-08-30 | PHARMACIA & UPJOHN COMPANY | Formyl- or cyano- substituted indole derivatives having dopaminergic activity |
| PE49195A1 (es) | 1993-12-07 | 1996-01-06 | Lilly Co Eli | Inhibidor de proteinquinasa |
| FR2746309B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| FR2793791B1 (fr) | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
| DK1325008T3 (da) | 2000-07-31 | 2006-02-13 | Hoffmann La Roche | Piperazinderivater |
| DE60112611T2 (de) | 2000-12-08 | 2006-06-14 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7970766B1 (en) | 2007-07-23 | 2011-06-28 | Google Inc. | Entity type assignment |
| MX2011002470A (es) * | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Pirimidinas macrociclicas como inhibidores de aurora cinasa. |
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| CA2740792C (en) | 2008-10-31 | 2016-06-21 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20110029480A1 (en) * | 2009-08-03 | 2011-02-03 | IntelliCubes, Inc. | Method of Compiling Multiple Data Sources into One Dataset |
| JP5624148B2 (ja) | 2009-10-13 | 2014-11-12 | エランコ・アニマル・ヘルス・アイルランド・リミテッド | 大環状インテグラーゼ阻害剤 |
| US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
| WO2011071725A1 (en) | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| EP2508607A1 (en) * | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| AU2012299218A1 (en) | 2011-08-19 | 2014-02-20 | Merck Sharp & Dohme Corp. | Crystal forms of a HCV protease inhibitor |
| WO2013045702A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor |
| WO2013045701A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor |
| GB2495134B (en) | 2011-09-30 | 2014-06-11 | Tridonic Uk Ltd | Power supply apparatus |
| US9090630B2 (en) * | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
| CN104394869A (zh) | 2011-10-20 | 2015-03-04 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 |
| AP2014007881A0 (en) | 2012-03-06 | 2014-08-31 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| MX347917B (es) * | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
| EP2645540A1 (de) | 2012-03-28 | 2013-10-02 | Siemens Aktiengesellschaft | Glimmschutzwerkstoff für eine elektrische Maschine |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| EP2951174B1 (en) | 2013-01-30 | 2017-04-26 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| WO2014173928A1 (en) | 2013-04-23 | 2014-10-30 | Lek Pharmaceuticals D.D. | Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof |
| EP3026051A4 (en) | 2013-07-24 | 2017-03-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| USRE50634E1 (en) | 2014-01-24 | 2025-10-14 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| WO2016070241A1 (en) | 2014-11-03 | 2016-05-12 | Ctxt Pty Ltd | Triazine compounds, compositions and synthesis |
| HUE067779T2 (hu) | 2014-12-15 | 2024-11-28 | Cmg Pharmaceutical Co Ltd | Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként |
| WO2016133838A1 (en) | 2015-02-20 | 2016-08-25 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| EP3267996B1 (en) | 2015-03-12 | 2020-11-11 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| AU2016257302A1 (en) | 2015-05-05 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2017002023A2 (en) | 2015-06-29 | 2017-01-05 | Q-Core Medical Ltd. | Methods circuits devices assemblies systems and associated computer executable code for sensing and analyzing fluid characteristics within a conduit of a medical device and air bubbles therein |
| RU2732405C2 (ru) | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| LT3319969T (lt) | 2015-07-06 | 2024-06-10 | Turning Point Therapeutics, Inc. | Diarilo makrociklo polimorfas |
| US20180325901A1 (en) | 2015-07-21 | 2018-11-15 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles and uses thereof |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CA3016182C (en) | 2016-03-04 | 2024-02-27 | Vanderbilt Universtiy | Substituted indole mcl-1 inhibitors |
| BR112019001607A2 (pt) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| JP2020533269A (ja) | 2016-12-14 | 2020-11-19 | デベロップメント センター フォー バイオテクノロジー | 抗体−薬物複合体およびその使用 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| ES2986593T3 (es) | 2017-07-28 | 2024-11-12 | Turning Point Therapeutics Inc | Compuestos macrocíclicos y usos de los mismos |
-
2015
- 2015-01-23 US US18/147,888 patent/USRE50634E1/en active Active
- 2015-01-23 HR HRP20191283TT patent/HRP20191283T1/hr unknown
- 2015-01-23 SG SG10202000191YA patent/SG10202000191YA/en unknown
- 2015-01-23 SI SI201530810T patent/SI3097107T1/sl unknown
- 2015-01-23 AP AP2016009383A patent/AP2016009383A0/en unknown
- 2015-01-23 US US15/113,583 patent/US9714258B2/en not_active Ceased
- 2015-01-23 DK DK19169041.1T patent/DK3572416T3/da active
- 2015-01-23 HR HRP20221518TT patent/HRP20221518T1/hr unknown
- 2015-01-23 NZ NZ761094A patent/NZ761094A/en unknown
- 2015-01-23 MY MYPI2016001385A patent/MY193524A/en unknown
- 2015-01-23 EA EA201691492A patent/EA031863B1/ru active IP Right Revival
- 2015-01-23 NZ NZ722375A patent/NZ722375A/en unknown
- 2015-01-23 EP EP19212126.7A patent/EP3636650A1/en not_active Withdrawn
- 2015-01-23 RS RS20240447A patent/RS65417B1/sr unknown
- 2015-01-23 HU HUE19169041A patent/HUE060554T2/hu unknown
- 2015-01-23 ES ES15740510T patent/ES2735729T3/es active Active
- 2015-01-23 MX MX2020001360A patent/MX392904B/es unknown
- 2015-01-23 EP EP23220719.1A patent/EP4338739A3/en active Pending
- 2015-01-23 DK DK15740510.1T patent/DK3097107T3/da active
- 2015-01-23 SI SI201531908T patent/SI3572416T1/sl unknown
- 2015-01-23 KR KR1020167020188A patent/KR102402179B1/ko active Active
- 2015-01-23 PL PL19212110.1T patent/PL3636649T3/pl unknown
- 2015-01-23 SG SG11201605929RA patent/SG11201605929RA/en unknown
- 2015-01-23 EP EP19212106.9A patent/EP3636648A1/en not_active Withdrawn
- 2015-01-23 SM SM20240175T patent/SMT202400175T1/it unknown
- 2015-01-23 SI SI201531994T patent/SI3636649T1/sl unknown
- 2015-01-23 DK DK19212110.1T patent/DK3636649T3/da active
- 2015-01-23 ES ES19169041T patent/ES2933350T3/es active Active
- 2015-01-23 SM SM20230008T patent/SMT202300008T1/it unknown
- 2015-01-23 UA UAA201608991A patent/UA121206C2/uk unknown
- 2015-01-23 RS RS20190900A patent/RS59059B1/sr unknown
- 2015-01-23 PE PE2016000959A patent/PE20160931A1/es unknown
- 2015-01-23 LT LTEP15740510.1T patent/LT3097107T/lt unknown
- 2015-01-23 RS RS20221161A patent/RS63829B1/sr unknown
- 2015-01-23 EP EP15740510.1A patent/EP3097107B1/en active Active
- 2015-01-23 ES ES19212110T patent/ES2976459T3/es active Active
- 2015-01-23 EP EP19169041.1A patent/EP3572416B1/en active Active
- 2015-01-23 LT LTEP19212110.1T patent/LT3636649T/lt unknown
- 2015-01-23 JP JP2016566857A patent/JP6490713B2/ja active Active
- 2015-01-23 HU HUE15740510A patent/HUE045208T2/hu unknown
- 2015-01-23 PL PL15740510T patent/PL3097107T3/pl unknown
- 2015-01-23 EA EA201892241A patent/EA201892241A1/ru unknown
- 2015-01-23 PL PL19169041.1T patent/PL3572416T3/pl unknown
- 2015-01-23 PT PT191690411T patent/PT3572416T/pt unknown
- 2015-01-23 CN CN201910549014.1A patent/CN110317213B/zh active Active
- 2015-01-23 PT PT192121101T patent/PT3636649T/pt unknown
- 2015-01-23 WO PCT/US2015/012597 patent/WO2015112806A2/en not_active Ceased
- 2015-01-23 EP EP19212110.1A patent/EP3636649B1/en active Active
- 2015-01-23 SM SM20190388T patent/SMT201900388T1/it unknown
- 2015-01-23 HR HRP20240503TT patent/HRP20240503T1/hr unknown
- 2015-01-23 HU HUE19212110A patent/HUE066590T2/hu unknown
- 2015-01-23 FI FIEP19212110.1T patent/FI3636649T3/fi active
- 2015-01-23 AU AU2015209239A patent/AU2015209239B2/en active Active
- 2015-01-23 LT LTEP19169041.1T patent/LT3572416T/lt unknown
- 2015-01-23 CA CA2936079A patent/CA2936079C/en active Active
- 2015-01-23 MX MX2016009588A patent/MX2016009588A/es active IP Right Grant
- 2015-01-23 CN CN201910549748.XA patent/CN110317214B/zh active Active
- 2015-01-23 CN CN201580005705.5A patent/CN106170289B/zh active Active
- 2015-01-23 PT PT15740510T patent/PT3097107T/pt unknown
-
2016
- 2016-07-07 ZA ZA2016/04654A patent/ZA201604654B/en unknown
- 2016-07-20 IL IL246860A patent/IL246860B/en active IP Right Grant
- 2016-07-22 CL CL2016001876A patent/CL2016001876A1/es unknown
- 2016-07-25 PH PH12016501463A patent/PH12016501463A1/en unknown
-
2017
- 2017-05-31 US US15/609,962 patent/US10246466B2/en active Active
-
2018
- 2018-11-29 US US16/204,566 patent/US10618912B2/en active Active
-
2019
- 2019-02-27 JP JP2019034652A patent/JP2019104748A/ja not_active Withdrawn
- 2019-07-17 CY CY20191100764T patent/CY1121850T1/el unknown
- 2019-08-21 IL IL268820A patent/IL268820B/en unknown
- 2019-12-10 AU AU2019279951A patent/AU2019279951B2/en active Active
-
2020
- 2020-02-21 US US16/797,866 patent/US20200216465A1/en not_active Abandoned
- 2020-07-06 ZA ZA2020/04100A patent/ZA202004100B/en unknown
-
2021
- 2021-01-07 JP JP2021001588A patent/JP2021063121A/ja active Pending
- 2021-09-27 US US17/485,942 patent/US20220112213A1/en not_active Abandoned
-
2022
- 2022-07-08 JP JP2022110613A patent/JP7356546B2/ja active Active
-
2023
- 2023-07-28 US US18/227,561 patent/US12404281B2/en active Active
- 2023-09-22 JP JP2023158350A patent/JP2023179539A/ja not_active Ceased
-
2025
- 2025-03-12 NL NL301322C patent/NL301322I2/nl unknown
- 2025-03-13 NO NO2025015C patent/NO2025015I1/no unknown
- 2025-03-20 FI FIC20250015C patent/FIC20250015I1/fi unknown
- 2025-03-20 HU HUS2500016C patent/HUS2500016I1/hu unknown
- 2025-04-08 LT LTPA2025513C patent/LTPA2025513I1/lt unknown
- 2025-04-09 FR FR25C1013C patent/FR25C1013I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404281B2 (en) | Diaryl macrocycles as modulators of protein kinases | |
| TWI736134B (zh) | 作為蛋白質激酶之調節劑的二芳基巨環 | |
| HK40028407B (en) | Diaryl macrocycles as modulators of protein kinases | |
| HK40109104A (en) | Diaryl macrocycles as modulators of protein kinases | |
| HK40028407A (en) | Diaryl macrocycles as modulators of protein kinases | |
| EA041662B1 (ru) | Способ ингибирования протеин- или тирозинкиназы в клетке с применением диарильного макроциклического соединения | |
| HK40015633B (en) | Diaryl macrocycles as modulators of protein kinases | |
| HK40015634B (en) | Diaryl macrocycles as modulators of protein kinases | |
| HK40015633A (en) | Diaryl macrocycles as modulators of protein kinases | |
| HK1231407B (zh) | 作为蛋白质激酶的调节剂的二芳基巨环 | |
| BR112016017101B1 (pt) | Compostos diaril macrociclos como moduladores das proteínas quinases e sua composição farmacêutica |